Drugs / ABNCoV2
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04839146 | Mar → Dec 2021 | COVID-19, severe acute respiratory syndrome | Radboud University Medical Center | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05077267 | Aug 2021 → Feb 2022 | COVID-19 | Bavarian Nordic | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05329220 | Aug 2022 → Mar 2023 | COVID-19 | Bavarian Nordic | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABNCoV2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05077267 ↗ |
| Modality | Vaccine | “ABNCoV2 vaccine” NCT05077267 ↗ |
| Route | Intramuscular | “Participants were vaccinated intramuscularly” PMID 36681093 ↗ Jan 2023 |